La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Bio-Gene Technology Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Bio-Gene Technology ha un patrimonio netto totale di A$3.7M e un debito totale di A$0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente A$4.3M e A$601.6K.

Informazioni chiave

Rapporto debito/patrimonio netto

AU$0

Debito

Indice di copertura degli interessi	n/a
Contanti	AU$2.21m
Patrimonio netto	AU$2.79m
Totale passività	AU$368.45k
Totale attività	AU$3.16m

Aggiornamenti recenti sulla salute finanziaria

We're Hopeful That Bio-Gene Technology (ASX:BGT) Will Use Its Cash Wisely

Feb 22

Here's Why We're Not Too Worried About Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Oct 25

Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Jun 20

Recent updates

We're Hopeful That Bio-Gene Technology (ASX:BGT) Will Use Its Cash Wisely

Feb 22

Here's Why We're Not Too Worried About Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Oct 25

Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Jun 20

Bio-Gene Technology Limited (ASX:BGT) Is Expected To Breakeven In The Near Future

Apr 28

What We Learned About Bio-Gene Technology's (ASX:BGT) CEO Compensation

Jan 11

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( A$4.1M ) di BGT superano le sue passività a breve termine ( A$572.9K ).

Passività a lungo termine: Le attività a breve termine di BGT ( A$4.1M ) superano le sue passività a lungo termine ( A$28.7K ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: BGT è esente da debiti.

Riduzione del debito: BGT non ha avuto debiti negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: BGT ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: BGT ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 7.5 % ogni anno

Bio-Gene Technology Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

We're Hopeful That Bio-Gene Technology (ASX:BGT) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Recent updates

New major risk - Share price stability

New minor risk - Financial data availability

New minor risk - Share price stability

Bio-Gene Technology Limited Approves the Election of Alex Ding as Director

Bio-Gene Technology Limited Announces Resignation of Rodrigo Valencia as Joint CFO

Bio-Gene Technology Limited Announces the Appointment of Roger Mcpherson as Joint Company Secretary

Bio-Gene Technology Limited, Annual General Meeting, Nov 23, 2023

New minor risk - Shareholder dilution

New major risk - Financial position

Full year 2023 earnings released: AU$0.018 loss per share (vs AU$0.019 loss in FY 2022)

Bio-Gene Technology Limited Announces Managing Director Changes

New major risk - Market cap size

Bio-Gene Technology Limited Announces Changes to the Board

First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.01 loss in 1H 2022)

Bio-Gene Technology Limited Submits Application to Secure Additional IP for Qcidetm

No independent directors

Bio-Gene Technology Limited, Annual General Meeting, Nov 18, 2022

Full year 2022 earnings released: AU$0.019 loss per share (vs AU$0.017 loss in FY 2021)

No independent directors

Bio-Gene Technology Limited Announces Positive Stored Grain Pest Results

We're Hopeful That Bio-Gene Technology (ASX:BGT) Will Use Its Cash Wisely

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Bio-Gene Technology Limited Appoints Sarah Driessens as Head of Regulatory Affairs

Bio-Gene Technology Limited announced that it has received AUD 3.04775 million in funding

Bio-Gene Technology Limited announced that it expects to receive AUD 3.21931 million in funding

Here's Why We're Not Too Worried About Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Full year 2021 earnings released: AU$0.017 loss per share (vs AU$0.016 loss in FY 2020)

Forecast to breakeven in 2024

Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Bio-Gene Technology Limited (ASX:BGT) Is Expected To Breakeven In The Near Future

Bio-Gene Technology Limited Appoints James Joughin as Non-Executive Director of the Company and Chairman of Audit and Risk Committee, Effective 1 March 2021

Bio-Gene Technology Limited Announces Flavocide MoA Studies Confirm Target Site of Activity

First half 2021 earnings released: AU$0.01 loss per share (vs AU$0.009 loss in 1H 2020)

Bio-Gene Technology Limited Announces Positive Preliminary Results from Aquatic (Rainbow Trout) and Avian (Mallard Duck) Eco-Toxicity Studies

What We Learned About Bio-Gene Technology's (ASX:BGT) CEO Compensation

Bio-Gene Technology Limited Appoints Peter Beetham as Non- Executive Director, Effective from 21 December 2020

Bio-Gene Technology Limited Announces Changes of Directors

Full year earnings released - AU$0.016 loss per share

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane